|
|
||||||||
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Symposium Report |
1 Canadian Institutes for Health Research Multidisciplinary Research Group on Hypertension, Clinical Research Institute of Montreal, University of Montreal, Quebec, Canada
Abstract
Resistance arteries undergo structural changes (vascular remodelling) in hypertension. These changes involve media thickening, reduced lumen diameter and consequent increased media:lumen ratio. Cellular processes underlying these events include altered vascular smooth muscle cell (VSMC) growth, migration, differentiation and increased extracellular matrix abundance. Another factor contributing to remodelling is inflammation, associated with macrophage infiltration, fibrosis and increased expression of redox-sensitive pro-inflammatory genes. Among the factors involved in arterial remodelling, angiotensin (Ang) II appears to be one of the most important. Ang II, a multifunctional peptide with pleiotropic actions, modulates vasomotor tone, cell growth, apoptosis/anoikis, cell migration and extracellular matrix deposition. It is pro-inflammatory and it stimulates production of growth factors and vasoactive agents. The multiple actions of Ang II are mediated via complex intracellular signalling pathways including stimulation of the phosholipase C (PLC)inositol 1,4,5-trisphosphate (IP3)1,2-diacylglycerol (DAG) cascade, mitogen-activated protein (MAP) kinases, tyrosine kinases and RhoA/Rho kinase. Furthermore, Ang II elicits many of its (patho)physiological effects by stimulating reactive oxygen species (O2 and H2O2) generation through activation of vascular NAD(P)H oxidase. O2 and H2O2 in turn influence downstream signalling molecules including transcription factors, tyrosine kinases/phosphatases, Ca2+ channels and MAP kinases. Interaction between these systems is complex and dysregulation at any level may contribute to vascular remodelling. Targeting such molecules/pathways could prevent or induce regression of hypertensive vascular damage thereby ameliorating development of hypertension and preventing target organ damage. The present review discusses the role of Ang II in remodelling of resistance arteries, focusing on some signalling pathways involved in vascular growth and inflammation in hypertension.
(Received 1 April 2005;
accepted after revision 10 May 2005; first published online 12 May 2005)
Corresponding author R. Touyz: Canada Research Chair in Hypertension, Kidney Research Centre, Ottawa Health Research Institute/University of Ottawa, Room 1333A, 451 Smyth Road, Ottawa, K1H 8M5, Ontario, Canada. Email: rtouyz{at}uottawa.ca
This article has been cited by other articles:
![]() |
P. E. Gallagher, C. M. Ferrario, and E. A. Tallant MAP kinase/phosphatase pathway mediates the regulation of ACE2 by angiotensin peptides Am J Physiol Cell Physiol, November 1, 2008; 295(5): C1169 - C1174. [Abstract] [Full Text] [PDF] |
||||
![]() |
B. I. Levy, E. L. Schiffrin, J.-J. Mourad, D. Agostini, E. Vicaut, M. E. Safar, and H. A.J. Struijker-Boudier Impaired Tissue Perfusion: A Pathology Common to Hypertension, Obesity, and Diabetes Mellitus Circulation, August 26, 2008; 118(9): 968 - 976. [Full Text] [PDF] |
||||
![]() |
A.C. Montezano, G.E. Callera, A. Yogi, Y. He, R.C. Tostes, G. He, E.L. Schiffrin, and R.M. Touyz Aldosterone and Angiotensin II Synergistically Stimulate Migration in Vascular Smooth Muscle Cells Through c-Src-Regulated Redox-Sensitive RhoA Pathways Arterioscler. Thromb. Vasc. Biol., August 1, 2008; 28(8): 1511 - 1518. [Abstract] [Full Text] [PDF] |
||||
![]() |
F. Feihl, L. Liaudet, B. I. Levy, and B. Waeber Hypertension and microvascular remodelling Cardiovasc Res, May 1, 2008; 78(2): 274 - 285. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. T. Pleger, D. M. Harris, C. Shan, L. E. Vinge, J. K. Chuprun, B. Berzins, W. Pleger, C. Druckman, M. Volkers, J. Heierhorst, et al. Endothelial S100A1 Modulates Vascular Function via Nitric Oxide Circ. Res., April 11, 2008; 102(7): 786 - 794. [Abstract] [Full Text] [PDF] |
||||
![]() |
C. Zeng, I. Armando, Y. Luo, G. M. Eisner, R. A. Felder, and P. A. Jose Dysregulation of dopamine-dependent mechanisms as a determinant of hypertension: studies in dopamine receptor knockout mice Am J Physiol Heart Circ Physiol, February 1, 2008; 294(2): H551 - H569. [Abstract] [Full Text] [PDF] |
||||
![]() |
P. Xu, A. C. Costa-Goncalves, M. Todiras, L. A. Rabelo, W. O. Sampaio, M. M. Moura, S. Sousa Santos, F. C. Luft, M. Bader, V. Gross, et al. Endothelial Dysfunction and Elevated Blood Pressure in Mas Gene-Deleted Mice Hypertension, February 1, 2008; 51(2): 574 - 580. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. M. Jonk, A. J. H. M. Houben, R. T. de Jongh, E. H. Serne, N. C. Schaper, and C. D. A. Stehouwer Microvascular Dysfunction in Obesity: A Potential Mechanism in the Pathogenesis of Obesity-Associated Insulin Resistance and Hypertension Physiology, August 1, 2007; 22(4): 252 - 260. [Abstract] [Full Text] [PDF] |
||||
![]() |
O. Khorram, M. Momeni, M. Desai, and M. G. Ross Nutrient Restriction In Utero Induces Remodeling of the Vascular Extracellular Matrix in Rat Offspring Reproductive Sciences, January 1, 2007; 14(1): 73 - 80. [Abstract] [PDF] |
||||
![]() |
K. E. Bernstein Views of the Renin-Angiotensin System: Brilling, Mimsy, and Slithy Tove Hypertension, March 1, 2006; 47(3): 509 - 514. [Abstract] [Full Text] [PDF] |
||||
![]() |
B. Musicki and A. L. Burnett eNOS Function and Dysfunction in the Penis Experimental Biology and Medicine, February 1, 2006; 231(2): 154 - 165. [Abstract] [Full Text] [PDF] |
||||
![]() |
I. McGrath New aspects of artery resistance and structure Exp Physiol, July 1, 2005; 90(4): 447 - 447. [Full Text] [PDF] |
||||
![]() |
J. C McGrath, C. Deighan, A. M Briones, M. M. Shafaroudi, M. McBride, J. Adler, S. M Arribas, E. Vila, and C. J Daly New aspects of vascular remodelling: the involvement of all vascular cell types Exp Physiol, July 1, 2005; 90(4): 469 - 475. [Abstract] [Full Text] [PDF] |
||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |